<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02418650</url>
  </required_header>
  <id_info>
    <org_study_id>3104005</org_study_id>
    <nct_id>NCT02418650</nct_id>
  </id_info>
  <brief_title>Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects</brief_title>
  <acronym>ARIADME</acronym>
  <official_title>A Two-Part Open-Label, Single-Centre Mass Balance, Pharmacokinetics, Biotransformation and Absolute Bioavailability Study of ODM-201 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate absolute bioavailability of ODM-201 and to determine the mass balance
      and routes of excretion of ODM-201 in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      6 healthy male subjects will be enrolled in part 1 and part 2 of the study, respectively
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of 14C-ODM-201 dose excreted and cumulative amount excreted in urine and faeces and total. Amount excreted and cumulative amount excreted in urine, faeces and total expressed as a percentage of the administered dose.</measure>
    <time_frame>Urine and faecal samples are collected baseline (Day-1) 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Metabolite profile of 14C-ODM-201 in plasma, urine and faeces</measure>
    <time_frame>up to 14 days post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum concentration (Cmax) of 14C-radioactivity in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to maximum concentration (tmax) of 14C-radioactivity in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-t)) of 14C-radioactivity in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-infinity)) of 14C-radioactivity in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half life (t1/2) of 14C-radioactivity in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum concentration (Cmax) of ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to maximum concentration (tmax) of ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-t)) of ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-infinity)) of ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half life (t1/2) of ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum concentration (Cmax) of metabolite ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to maximum concentration (tmax) of metabolite ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-t)) of metabolite ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-infinity)) of metabolite ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half life (t1/2) of metabolite ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum concentration (Cmax) of metabolite 14C-ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to maximum concentration (tmax) of metabolite 14C-ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-t)) of metabolite 14C-ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-infinity)) of metabolite 14C-ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half life (t1/2) of metabolite 14C-ORM 15341 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum concentration (Cmax) of 14C-ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to maximum concentration (tmax) of 14C-ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-t)) of 14C-ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-infinity)) of 14C-ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half life (t1/2) of 14C-ODM-201 in plasma</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum concentration (Cmax) of 14C-radioactivity in whole blood</measure>
    <time_frame>The samples were taken 24 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to maximum concentration (tmax) of 14C-radioactivity in whole blood</measure>
    <time_frame>The samples were taken 24 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration-time curve (AUC(0-t)) of 14C-radioactivity in whole blood</measure>
    <time_frame>The samples were taken 24 h post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Renal elimination for ODM-201 in urine</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 14 d post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Renal elimination for 14C-ODM-201 in urine</measure>
    <time_frame>The samples were taken up-to 14 d post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fraction absorbed (FA) of total radioactivity based on urinary recovery of total radioactivity for both IV and oral dosing</measure>
    <time_frame>The samples were taken 72 h post-dose after IV dosing and up-to 14 d post-dose after oral solution dosing</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Collected 7 days post-dose in part 1 and up to 14 days post-dose in part 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>Assessed at screening, pre-dose, at discharge from the study centre (72 h and 7 d post-dose in part 1 and latest at 14 d post-dose in part 2)</time_frame>
    <description>Full physical examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Assessed at screening, pre-dose, 3 h, 5 h, 12 h, 24 h, 36 h and 48 h post-dose and at discharge from the study centre (72 h post-dose in part 1 and latest at 14 d post-dose in part 2) and in addition in part 1 7 d post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>Assessed at screening, pre-dose, 3 h, 5 h, 12 h, 24 h, 36 h and 48 h post-dose and at discharge from the study centre (72 h post-dose in part 1 and latest at 14 d post-dose in part 2) and in addition in part 1 7 d post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Oral temperature</measure>
    <time_frame>Assessed at screening, pre-dose, 3 h, 5 h, 12 h, 24 h, 36 h and 48 h post-dose and at discharge from the study centre (72 h post-dose in part 1 and latest at 14 d post-dose in part 2) and in addition in part 1 7 d post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>Assessed at screening, pre-dose, 3 h, 5 h, 12 h, 24 h, 36 h and 48 h post-dose and at discharge from the study centre (72 h post-dose in part 1 and latest at 14 d post-dose in part 2) and in addition in part 1 7 d post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical chemistry</measure>
    <time_frame>Assessed at screening, pre-dose, 24 h and 48 h post-dose and 7 d post-dose in part 1 and latest at 14 d post-dose in part 2</time_frame>
    <description>Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin (Total), Calcium, Creatinine, Creatinine clearance, Lactate dehydrogenase, Potassium, Sodium and Urea</description>
  </other_outcome>
  <other_outcome>
    <measure>Haematology</measure>
    <time_frame>Assessed at screening, pre-dose, 24 h and 48 h post-dose and 7 d post-dose in part 1 and latest at 14 d post-dose in part 2</time_frame>
    <description>Basophils, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes, MCH, MCHC, MCV, Monocytes, Neutrophils, Red Blood Cell Count, White Blood Cell Count and Thrombocytes</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Assessed at screening, pre-dose, 24 h and 48 h post-dose and 7 d post-dose in part 1 and latest at 14 d post-dose in part 2</time_frame>
    <description>Leucocytes, protein, erythrocytes, glucose and specific gravity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral 300 mg tablet of ODM-201 followed by single intravenous 100 microg of 14C-ODM-201 containing not more than 37 kBq (1000 nCi)14C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral solution of 300 mg 14C-ODM-201 containing no more than 6.3 MBq (171 microCi) 14C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-201 300 mg tablet</intervention_name>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous14C-ODM-201</intervention_name>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 mg 14C-ODM-201 oral solution</intervention_name>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy males

          -  Aged 50 to 65 years (inclusive)

          -  Normal weight defined as a body mass index (BMI) of &gt;18.5 and &lt;32.0 kg/m2

          -  Weight 55 to 100 kg (inclusive)

          -  Adequate method of contraception during the study and for a period of 6 months after
             study drug administration

        Key exclusion Criteria:

          -  Evidence of clinically significant disease

          -  Intake of any medication that could affect the outcome of the study

          -  Known hypersensitivity to the active substances or the excipients of the drug or any
             serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients

          -  History of anaphylactic/anaphylactoid reactions

          -  Clinically significant abnormal biochemistry, haematology or urinalysis

          -  Current or history of any drug or alcohol abuse in the past 2 years

          -  Regular alcohol consumption &gt;21 units per week (1 unit = ½ pint beer, 25 mL of 40%
             spirit or a 125 mL glass of wine)

          -  Current use or use within the last 12 months of nicotine products

          -  Positive drugs of abuse test result

          -  Positive hepatitis B surface antigen, hepatitis C virus antibody or human
             immunodeficiency virus results

          -  Presence or history of clinically significant allergy requiring treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Evans, MB ChB MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

